(arrow C)), with one small island of peri-limbal white sclera supero-temporally. The sclera was too thin posteriorly for a tube or valve.
There appears to be, however, a misconception between the usage of intracameral cefuroxime and its perceived protective effect against PE secondary to enterococci. Cefuroxime is a second-generation cephalosporin with an intrinsic lack of activity against enterococci owing to the production of low-affinity penicillin binding proteins and L,Dtranspeptidase. 2, 3 This is commonly referred to as the 'enterococci-gap'.
Putting this into the broader picture of the quoted EVS 4 vs the Swedish National Cataract Register Study, 5 the a priori lack of efficiency of cefuroxime against enterococci explains the higher prevalence of enterococciinduced PE in the Swedish group (29.9% vs 2.2%) and is not surprising.
Given that enterococci-induced PE is a considerable problem in the era of intracameral cefuroxime, it seems counterintuitive that the authors' standard choice for topical preoperative prophylaxis is a combination of Polymyxin B and Trimethoprim, both of which have low effectiveness against enterococci. Topical Chloramphenicol would seem a superior choice in this context.
It would have been interesting to know which species of bacteria the cluster of four PEs in 2005/2006 belonged to and whether intracameral cefuroxime had been given.
Sir, Response to Nestel
We thank Dr Nestel 1 for his interest in our study. 2 We found some associations between the pathogenic conjunctival bacteria and the systemic co-morbidities of patients undergoing cataract surgery, which was the main purpose of the study. Among these associations, we found that enterococci prevalence is associated with age and diabetes. Owing to the current wide use of intracameral cefuroxime for the cataract surgery prophylaxis, 3, 4 we introduced the example of the postoperative endophthalmitis (PE) caused by enterococci for illustrating the implications of our findings in the management of patients carrying conjunctival bacteria resistant to a particular prophylaxis, such as the enterococci to cefuroxime, as Dr Nestel pointed. The systemic co-morbidities associations with other bacteria (for instance multi-resistant Staphylococcus) could also help in choosing a prophylaxis.
The answers to other comments are as follows: K In the study design, polymyxin B plus trimethoprim eye drops is an empirical prophylaxis for all patients, except those having conjunctival pathogen bacteria resistant to these antibiotics, such as enterococci. We try not to increase the resistance to first-line antibiotic treatments.
K The occurrence of four PE cases in the first year of the study period 2 was before using intracameral cefuroxime. This fact could point to streptococci as the most likely cause, as there was no case of Streptococci-PE in the ESCRS groups treated with cefuroxime, 5 and no others prophylactic measures had changed in our study.
K The oral antibiotic for patients with conjunctival enterococci was chosen in accordance with their susceptibility tests; 6 quinolones being the first choice, if possible.
K Finally, the 'potential' risk of intraocular contamination by enterococci, in patients over 85 years, was calculated with respect to the conjunctival enterococci prevalence of patients younger than 86 years (Supplementary Table 3) . 2 This information is extended in Table 1 . 
